Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy.

Neuronal nitric oxide synthase (nNOS) membrane delocalization contributes to the pathogenesis of Duchenne muscular dystrophy (DMD) by promoting functional muscle ischemia and exacerbating muscle injury during exercise. We have previously shown that supra-physiological expression of nNOS-binding mini-dystrophin restores normal blood flow regulation and prevents functional ischemia in transgenic mdx mice, a DMD model. A critical next issue is whether systemic dual adeno-associated virus (AAV) gene therapy can restore nNOS-binding mini-dystrophin expression and mitigate muscle activity-related functional ischemia and injury. Here, we performed systemic gene transfer in mdx and mdx4cv mice using a pair of dual AAV vectors that expressed a 6 kb nNOS-binding mini-dystrophin gene. Vectors were packaged in tyrosine mutant AAV-9 and co-injected (5 × 10(12) viral genome particles/vector/mouse) via the tail vein to 1-month-old dystrophin-null mice. Four months later, we observed 30-50% mini-dystrophin positive myofibers in limb muscles. Treatment ameliorated histopathology, increased muscle force and protected against eccentric contraction-induced injury. Importantly, dual AAV therapy successfully prevented chronic exercise-induced muscle force drop. Doppler hemodynamic assay further showed that therapy attenuated adrenergic vasoconstriction in contracting muscle. Our results suggest that partial transduction can still ameliorate nNOS delocalization-associated functional deficiency. Further evaluation of nNOS binding mini-dystrophin dual AAV vectors is warranted in dystrophic dogs and eventually in human patients.

[1]  Dongsheng Duan,et al.  Evaluation of Muscle Function of the Extensor Digitorum Longus Muscle Ex vivo and Tibialis Anterior Muscle In situ in Mice , 2013, Journal of visualized experiments : JoVE.

[2]  D. Duan,et al.  α2 and α3 helices of dystrophin R16 and R17 frame a microdomain in the α1 helix of dystrophin R17 for neuronal NOS binding , 2012, Proceedings of the National Academy of Sciences.

[3]  D. Duan.  Duchenne muscular dystrophy gene therapy: Lost in translation? , 2011, Research and reports in biology.

[4]  D. Duan,et al.  Nitrosative stress elicited by nNOSµ delocalization inhibits muscle force in dystrophin‐null mice , 2011, The Journal of pathology.

[5]  K. Davies,et al.  Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin , 2010, Journal of Cell Science.

[6]  N. Bourg,et al.  Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. , 2010, Human molecular genetics.

[7]  D. Duan,et al.  Systemic Trans-splicing adeno-associated viral delivery efficiently transduces the heart of adult mdx mouse, a model for duchenne muscular dystrophy. , 2009, Human gene therapy.

[8]  D. Duan,et al.  Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. , 2009, The Journal of clinical investigation.

[9]  J. Kornegay,et al.  A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  L. Zhou,et al.  A canine minidystrophin is functional and therapeutic in mdx mice , 2008, Gene Therapy.

[11]  N. Muzyczka,et al.  Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses , 2008, Proceedings of the National Academy of Sciences.

[12]  D. Duan,et al.  Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration , 2007, Gene Therapy.

[13]  D. Duan,et al.  Expanding Adeno-associated Viral Vector Capacity: A Tale of Two Vectors , 2007, Biotechnology & genetic engineering reviews.

[14]  D. Duan,et al.  C-terminal-truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double-knockout mice. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  J. Chamberlain,et al.  Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex , 2006, Journal of Cell Science.

[16]  D. Duan,et al.  Viral serotype and the transgene sequence influence overlapping adeno‐associated viral (AAV) vector‐mediated gene transfer in skeletal muscle , 2006, The journal of gene medicine.

[17]  Dongsheng Duan,et al.  Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors , 2005, Nature Biotechnology.

[18]  L. Kunkel.  Cloning of the DMD Gene , 2005 .

[19]  S. Harper,et al.  Microdystrophin Gene Therapy of Cardiomyopathy Restores Dystrophin-Glycoprotein Complex and Improves Sarcolemma Integrity in the Mdx Mouse Heart , 2003, Circulation.

[20]  Dongsheng Duan,et al.  Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy , 2002, Nature Medicine.

[21]  D. Duan,et al.  Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  J. Faulkner,et al.  Force and power output of fast and slow skeletal muscles from mdx mice 6‐28 months old , 2001, The Journal of physiology.

[23]  G. D. Thomas,et al.  Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Duan,et al.  A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation , 2000, Nature Medicine.

[25]  W. Lim,et al.  Unexpected modes of PDZ domain scaffolding revealed by structure of nNOS-syntrophin complex. , 1999, Science.

[26]  P. Huang,et al.  Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  G. D. Thomas,et al.  Nitric oxide mediates contraction‐induced attenuation of sympathetic vasoconstriction in rat skeletal muscle , 1998, The Journal of physiology.

[28]  S. Takeda,et al.  [Gene therapy in muscular dystrophy]. , 1995, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[29]  K. Aldape,et al.  Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy , 1995, Cell.

[30]  A. Sébille,et al.  mdx mice show progressive weakness and muscle deterioration with age , 1995, Journal of the Neurological Sciences.

[31]  K. Davies,et al.  Very mild muscular dystrophy associated with the deletion of 46% of dystrophin , 1990, Nature.

[32]  E A Barnard,et al.  The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. , 1989, Science.

[33]  V. Chapman,et al.  Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Duan,et al.  Novel mini-dystrophin gene dual adeno-associated virus vectors restore neuronal nitric oxide synthase expression at the sarcolemma. , 2012, Human gene therapy.

[35]  D. Duan,et al.  Recombinant adeno-associated viral vector production and purification. , 2012, Methods in molecular biology.

[36]  Chady H Hakim,et al.  Monitoring murine skeletal muscle function for muscle gene therapy. , 2011, Methods in molecular biology.

[37]  James M. Allen,et al.  Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  D. Duan,et al.  Efficient transgene reconstitution with hybrid dual AAV vectors carrying the minimized bridging sequences. , 2011, Human gene therapy.

[39]  D. Duan.  Muscle Gene Therapy , 2011, Methods in Molecular Biology.

[40]  D. Duan,et al.  Evidence for the Failure of Adeno-associated Virus Serotype 5 to Package a Viral Genome ≥8.2 kb. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  D. Duan,et al.  Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[42]  D. Duan,et al.  Delivering Large Therapeutic Genes for Muscle Gene Therapy , 2010 .

[43]  D. Duan,et al.  A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[44]  D. Duan,et al.  Efficient Whole-body Transduction with Trans-splicing Adeno-associated Viral Vectors. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[45]  L. Kunkel.  2004 William Allan Award address. Cloning of the DMD gene. , 2005, American journal of human genetics.